Skip to main content
Clinical Trials/NL-OMON47140
NL-OMON47140
Completed
Phase 3

Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicenter trial. - COLOPEC

Academisch Medisch Centrum0 sites185 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
metastases of peritoneum
Sponsor
Academisch Medisch Centrum
Enrollment
185
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\) age between 18 and 75 years. (2\) adequate clinical condition to undergo re\-laparoscopy or re\-laparotomy within either 10 days or between week 5\-8 from primary resection. (3\) written informed consent (4\) white blood cell count at least 3000/mm3, platelet count at least 100\.000/mm3\. (5\) no bleeding diathesis or coagulopathy. (6\) creatinine normal or creatinine clearance at least 50 ml/min.

Exclusion Criteria

  • (1\) postoperative complications that interfere with adjuvant HIPEC within 8 weeks (i.e. persisting intra\-abdominal abscess, significant fascial dehiscence, enteric fistula). (2\) liver and/or lung metastases. (3\) pregnant or lactating women. (4\) unstable or uncompensated respiratory or cardiac disease. (5\) serious active infections. (6\) other concurrent chemotherapy. (7\) hypersensitivity for fluorouracil folinic acid (calciumfolinate) or another substance of leucovorin or Oxaliplatin. (8\) Stomatitis, ulceration in the mouth or gastrointestinal tract. (9\) severe diarrhea (10\) severe hepatic and / or renal dysfunction. (11\) plasma bilirubin concentrations greater than 85 \*mol/l. (12\) Pernicious anemia or other anaemias due to vitamin B12 deficiency.(13\) peripheral sensory neuropathy with functional impairment.

Outcomes

Primary Outcomes

Not specified

Similar Trials